Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $10.6 million.

  • Organogenesis Holdings' Share-based Compensation rose 13.02% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 18.02%. This contributed to the annual value of $10.6 million for FY2024, which is 17.59% up from last year.
  • As of FY2024, Organogenesis Holdings' Share-based Compensation stood at $10.6 million, which was up 17.59% from $9.0 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Share-based Compensation registered a high of $10.6 million during FY2024, and its lowest value of $1.7 million during FY2020.
  • For the 3-year period, Organogenesis Holdings' Share-based Compensation averaged around $8.7 million, with its median value being $9.0 million (2023).
  • Data for Organogenesis Holdings' Share-based Compensation shows a peak YoY spiked of 132.63% (in 2021) over the last 5 years.
  • Organogenesis Holdings' Share-based Compensation (Yearly) stood at $1.7 million in 2020, then spiked by 132.63% to $3.9 million in 2021, then skyrocketed by 69.57% to $6.6 million in 2022, then skyrocketed by 37.30% to $9.0 million in 2023, then increased by 17.59% to $10.6 million in 2024.